San Diego, 22–25 June. The BIO International Convention moved down the coast to San Diego for its 2026 edition under the printed theme “Driven by Purpose”, and the industry — some twenty thousand executives, business-development chiefs, venture partners, government officials and licensing counsel — showed up ready to work. If JPM26 in January had been the shape of the year’s ambition, BIO26 was the shape of the year’s execution: partnering meetings across four days, panel commentary on translational science, side sessions on China sourcing, and the same underlying strategic argument that has run through 2026’s biotech calendar — licensing over acquisition, partnering over building, disciplined capital over aggressive capital.
The BIO Partnering platform did what it does. Business-development teams walked into fifteen-minute meetings on tight rotations, generated shortlists, and left with follow-up calls booked for July. That is BIO’s actual product. The panels are the backdrop.
The Partnering machine as the year’s real product
BIO Partnering — the proprietary meeting-scheduling platform that anchors the convention — remained the single most consequential piece of business infrastructure at the show. Companies file profiles, licensing counterparties post specific asset descriptions, both sides run their preferences through the system, and the platform routes hundreds of thousands of one-to-one meetings across the four days. The industry has, over two decades, evolved this from a supplementary tool into the primary vehicle for early-stage business-development conversations. For a company sourcing a late-stage licence-in candidate, BIO Partnering is where the shortlist gets built.
The mood on the partnering side reflected what the pharmaceutical industry has been telegraphing for six months. Large pharma is buying capability — assets, platforms, capacity — through licensing arrangements rather than through outright M&A. Small-and-mid-cap biotech is willing to sell rights on structured terms rather than hold out for a full acquisition. The result is a partnering market that clears more deals, at more modular values, than at any BIO in the recent cycle.
The China chapter continues on the convention floor
The other under-appreciated feature of BIO 2026 was the visibility of Chinese biotechs on the convention floor and in the partnering rotations. If JPM 2026 was the meeting where nine Western-pharma-to-China licensing announcements had already occurred by the time it opened, and ASCO 2026 was the meeting where Chinese assets showed up on the plenary platform, BIO 2026 was the meeting where Chinese business-development teams built the deal pipeline for the second half of the year. Chinese biotechs are, increasingly, sitting on the sell-side of the Partnering conversation — not just as generic-drug producers, but as innovative-asset developers with global commercial ambition.
The political overlay has not softened. Export controls, technology-transfer scrutiny, and heightened political attention to China-anchored capital are the constants. What has changed is that the industry has decided the science is too important to leave off the table for policy reasons, and is structuring deals that work inside the political constraints.
AI-for-drug-discovery: the industry catches up to Nvidia-Lilly
The AI-for-drug-discovery track was one of the most attended in the panel programme. The industry’s leaders — Nvidia and Eli Lilly, whose January BIO26-parallel announcement of a five-year, $1 billion co-innovation lab set the reference standard — used the panel platform to describe the operational shape of the deployment. Others — Recursion, Insitro, Isomorphic Labs, Xaira, Absci, and the AI programmes at the largest pharmas — described their own approaches, and the audience compared notes.
The consensus, on any honest read, is that AI-for-drug-discovery has moved from thesis into production. Foundation models for molecular design, multimodal protein-and-ligand interaction modelling, and the compute-and-MLOps infrastructure that makes discovery pipelines reproducible are being deployed at industrial scale. Whether the deployment produces measurable pipeline productivity gains within the current programmes’ timelines is the question the industry will litigate at BIO 2027 with real data.
Cell and gene therapy: the operational conversation
The cell-and-gene-therapy conversation continued to mature toward operational reality. Manufacturing, vein-to-vein time, outpatient administration models, bridging therapy protocols, and payer reimbursement architecture dominated the sessions. The science is moving forward on multiple fronts — solid-tumour CAR-T (with the Chinese cohort increasingly visible), autoimmune indications, allogeneic platforms, and in-vivo delivery — and the industrial infrastructure has to keep up.
The economic argument is where the cell-therapy category will win or lose its next decade. Manufacturing cost curves, payer reimbursement architecture, and clinical-network operational capacity are the three levers. Companies that show progress on all three are getting the partnering meetings. Companies that show progress on only one are not.
Rare disease, obesity, immunology: three horizons
The panel programme organised the therapeutic conversation around three horizons. Rare disease continues to be a category where credible development leads to durable revenue and where regulatory pathways remain relatively navigable. Obesity — after Eli Lilly’s ascendancy and Novo Nordisk’s public acknowledgement of the current-generation position — has become a category with much broader indication interest (cardiovascular, metabolic, neurologic, addiction, sleep apnea) than the original weight-loss framing implied. Immunology, particularly in autoimmune indications, is the third horizon where the industry is investing serious capital against real unmet need.
The IPO market, and the middle-market squeeze
The biotech IPO market cracked open at JPM 2026 and continued to develop through BIO 2026. Several late-stage biotechs used BIO week to conduct testing-the-waters meetings, and a handful of near-term filings were telegraphed in fireside chats and press availability sessions. The window is disciplined rather than exuberant. Companies with Phase 3 or near-Phase-3 data, a clear pricing narrative, and defensible therapeutic-area positioning are getting priced. Companies with early-stage stories and a lot of hope are not.
The middle-market squeeze — small-cap biotechs with assets in Phase 2 or earlier development, less crossover-investor engagement, and thinner cash runway — remained visible. BIO 2026 was, for many of those companies, a partnering-or-perish moment.
Regulatory conversation: FDA’s evolving posture
The FDA regulatory sessions were substantive. Predetermined change-control plans for AI/ML-enabled Software as a Medical Device, real-world-evidence expectations, post-market surveillance obligations, accelerated-approval framework refinements, and the boundary between clinical-decision-support and regulated device were all discussed with senior FDA participation. The industry-regulator posture was constructive; the specifics were where the working sessions did the heavy lifting.
What BIO 2026 actually moved
- Licensing is the shape of the year’s deal book. Partnering meetings clear at scale; acquisitions are a shorter list.
- China is a first-class partnering counterparty. BIO 2027 will look different again.
- AI-for-drug-discovery has moved from thesis into production. The productivity data will settle the question by 2027.
- Cell and gene therapy is a manufacturing-and-reimbursement problem. The industrial infrastructure is the bottleneck.
- The IPO window is open but disciplined. Late-stage stories with clear pricing narratives are pricing.
Open questions
Do the licensing deals struck at BIO 2026 translate into clinical and commercial productivity by 2028, or does the industry re-argue the balance between licence-in and build once the current cycle’s assets read out? Does the Chinese biotech sourcing chapter absorb the political risk it is running on, or does policy narrow the licence-in pipeline? And does AI-for-drug-discovery produce the compressed timelines the industry is planning around?
Bottom line: BIO 2026 was the biotech industry running the operational version of the strategy it announced at JPM in January. The Partnering platform delivered. The licence-in playbook worked. China stayed on the deal table. AI-for-drug-discovery moved from panel topic to industrial deployment. The measure of success at BIO 2028 will be whether the assets that changed hands at San Diego this week deliver the pipelines they promised.
